

# Molecular Epidemiology of Group B *Streptococcus* Isolates from Pregnant Women with Premature Rupture of Membranes in Fuzhou, China

Bin Liang<sup>1,\*</sup>, Huiyu Chen<sup>2,\*</sup>, Donghong Yu<sup>3,4</sup>, Wantong Zhao<sup>1,3</sup>, Xiaoling Cai<sup>1,3</sup>, Huahong Qiu<sup>2</sup>, Liangpu Xu<sup>1</sup>

<sup>1</sup>Medical Genetic Diagnosis and Therapy Center, Fujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, People's Republic of China; <sup>2</sup>Laboratory Department, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, People's Republic of China; <sup>3</sup>Fujian Obstetrics and Gynecology Hospital, Fuzhou, Fujian, People's Republic of China; <sup>4</sup>Medical Research Center, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Liangpu Xu; Huahong Qiu, Fujian Maternity and Child Health Hospital, Fuzhou, 350001, People's Republic of China, Tel +86-0591-87554929; +86-0591-87604121, Email xiliangpu@fjmu.edu.cn; 722hhq@sina.com

**Objective:** This study investigated the molecular epidemiology of Group B *Streptococcus* (GBS) in pregnant women with premature rupture of membranes (PROM) in Fuzhou region of China as a source of clinical reference.

**Methods:** GBS isolates were obtained from pregnant women with PROM. All isolates were genotyped, serotyped, and tested for drug-resistance and virulence genes using PCR and DNA sequencing. Antibiotic susceptibility testing was performed using the Vitek<sup>®</sup> 2 automated system.

**Results:** Among the 140 GBS isolates, seventeen sequence types (STs) were identified, of which ST19 (20.0%) was the most prevalent, followed by ST862, ST10, and ST12. Three clonal complexes (CC19, CC10 and CC1) were identified. The predominant serotype was III (45.7%), followed by V (23.6%), Ib (18.6%), Ia (7.1%), and II (3.6%). The prevalence of multidrug resistance was 72.8% (102/140). All isolates were susceptible to penicillin G, ampicillin, quinupristin, linezolid, vancomycin, and tigecycline. The majority of isolates were resistant to erythromycin (70.0%), clindamycin (72.1%), and tetracycline (81.4%), and 28.6% of isolates were resistant to levofloxacin and moxifloxacin. Of the 98 erythromycin-resistant strains, *mreA*, *ermB*, *mefA*, *mefE*, *ermA*, and *ermTR* were detected in 100%, 70.4%, 49.0%, 22.4%, 13.3%, and 9.2%, respectively. No *linB* was detected among 101 clindamycin-resistant strains. Of the 114 tetracycline-resistant strains, *tetM*, *tetK*, *tetL* and *tetO* were detected in 52.6%, 61.4%, 7.9%, and 23.7%, respectively. Regarding virulence genes, all strains carried *rib* and *hylB*, followed by *scpB* (98.6%), and *bca* (80.7%), whereas only one strain carried *bac*.

**Conclusion:** ST19/III and ST862/III were the most prevalent GBS subtypes. Penicillin G remains a first-line antibiotic for intrapartum antibiotic prophylaxis and treatment of GBS infections. The prevalence of resistance to clindamycin, erythromycin, and tetracycline is high among GBS isolates in the Fuzhou region. ST862 and ST651 are emerging animal origin STs in human infections, and may become potential zoonotic threats.

**Keywords:** Group B *Streptococcus*, molecular epidemiology, premature rupture of the membranes, antibiotic resistance, China

## Background

*Streptococcus agalactiae*, also known as Group B *Streptococcus* (GBS), commonly colonizes the lower gastrointestinal and genitourinary tracts of pregnant women with a prevalence of 10–35%.<sup>1</sup> Maternal GBS colonization may contribute to preterm delivery, maternal fever, and premature rupture of membranes (PROM), which may lead to ascending infection and early-onset disease (EOD) in the neonate, including neonatal pneumonia, sepsis, and meningitis.<sup>2</sup> Universal GBS

screening at 35–37 weeks gestation, and intrapartum antibiotic prophylaxis for GBS-positive women effectively prevents neonatal GBS-EOD.<sup>3</sup> Clinically, penicillin is a first-line antibiotic for IAP and treatment of GBS infections; however, GBS strains with reduced susceptibility to penicillin have been reported in Hong Kong,<sup>4</sup> Japan,<sup>5,6</sup> USA,<sup>7</sup> and Korea.<sup>8</sup> In addition, the prevalence of resistance to second-line antibiotics is high among GBS isolates in China. A systematic review and meta-meta-analysis of the incidence of GBS disease in infants, and the prevalence of antimicrobial resistance (AMR) in China revealed that the highest prevalence of resistance was tetracycline (median 98.0%, interquartile range [IQR] 80.0–100%), followed by clindamycin (73.3%, IQR 62.6–78.7%), erythromycin (64.4%, IQR 56.6–75%), and ciprofloxacin (25.0%, IQR 9.1–35.2%).<sup>9</sup> GBS has also been reported to have a high prevalence of AMR in some other countries in recent years.<sup>10–13</sup> The high level of AMR in China may be attributable to the widespread use of antibiotics in past decades and the development of resistance mutations under the selection pressure of antibiotic treatment for GBS disease. Thus, it is critical to determine the antibiotic susceptibility profile of GBS isolates in clinical practice and to select antibiotics accordingly.

One strategy for preventing invasive GBS disease is to develop specific vaccines.<sup>14</sup> Capsular polysaccharide (CPS) is the main virulence factor of GBS strains, and is recognized as a candidate antigenic epitope for vaccines.<sup>15</sup> To date, 10 known serotypes (Ia, Ib, and II–IX) have been categorized based on their CPS composition, among which serotype III is the most common among GBS strains inducing invasive disease.<sup>16–18</sup> According to the PubMLST website (<https://pubmlst.org/organisms/streptococcus-agalactiae>), a total of 1954 sequence types (STs) have been identified (up to June 15, 2022) using multilocus sequence typing (MLST). Previous studies have found regional and ethnic variations in the incidence of GBS infection and serotype and genotype distribution in pregnant women.<sup>1,19,20</sup> In pregnant women, different GBS serotypes and genotypes have different levels of pathogenicity and are associated with different levels of risk of neonatal GBS-EOD.<sup>21</sup> Therefore, knowledge of the serotypes, genotypes, virulence factors, and drug-resistance profiles of GBS strains in a region could help clinicians to identify high-risk pregnant women and infants for monitoring and treatment, and benefit the development of specific GBS vaccines. This study aimed to describe the molecular characteristics and drug-resistance profile of GBS colonization among pregnant women admitted to a large maternity hospital with premature rupture of membranes, to provide data to support the prevention and treatment of GBS colonization in the region.

## Materials and Methods

### Study Setting and Sample Collection and Identification

The study was conducted at Fujian Provincial Maternity and Child Health Hospital in Fuzhou, Fujian, China, from June 2020 to April 2021. The hospital delivers almost 20,000 infants annually. As universal screening of pregnant women for GBS at 35–37 gestational weeks has not been implemented in the hospital, the GBS isolates were obtained from pregnant women hospitalized with PROM.

The GBS detection was performed as follows: vaginal or cervical swabs were inoculated onto Columbia blood agar (Bioivt, Zhengzhou, China) and incubated at 37°C in 5% CO<sub>2</sub> for 18–24 h. Colonies that were rounded, gray, translucent, with a smooth surface, with or without beta-hemolytic activity, on blood agar were considered suspected GBS and were selected to undergo confirmatory testing using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (BD MALDI Bruker Biotyper, Bremen, Germany). GBS identification was performed by staff in the bacteriological laboratory of Fujian Maternity and Child Health Hospital.

### Genomic DNA Extraction

For subsequent molecular assays, a single GBS colony was selected from the blood agar culture, and mixed with 1.0 mL of sterile normal saline in a 1.5 mL centrifuge tube to prepare the bacterial suspension. Genomic DNA was extracted by heat lysis. Briefly, 0.5 mL of GBS bacterial suspension was centrifuged at 13,000 × g for 10 min and then the precipitate was suspended in 100 µL DNA extracting solution (10 mM Tris-HCl, pH 8.5, 1 mM EDTA, and 1% Triton X-100). The suspension was heated at 99°C for 10 min, followed by centrifugation at 13,000 × g for 10 min. The supernatant was stored at –20°C until use.

## Multilocus Sequence Typing

The MLST analysis was carried out in accordance with the *Streptococcus agalactiae* MLST protocol. Seven house-keeping genes (*adhP*, *pheS*, *atr*, *glnA*, *sdhA*, *glcK*, and *tkt*) were amplified by PCR using oligonucleotide primers, as described previously.<sup>22</sup> The resulting PCR products were sequenced by Sangon Biotech Co. Ltd. (Shanghai, China). The data were then submitted to the GBS MLST database (<https://pubmlst.org/organisms/streptococcus-agalactiae>) to assign alleles at the seven loci, and each isolate was classified according to the ST. Strains were assigned to a clonal complex (CC) according to an MLST profile downloaded from the PubMLST website (see the [Supplemental Material](#)).

## Serotyping

Each isolate was serotyped based on the capsule type using a real-time PCR assay, as described previously.<sup>23</sup> The isolate was defined as non-typeable (NT) if the real-time PCR assay failed to identify any serotype.

## Antimicrobial Resistance Testing

Antimicrobial resistance testing was performed using the Vitek<sup>®</sup> 2 automated system (bioMérieux, Marcy L'Étoile, France). The samples were tested for susceptibility to penicillin G, ampicillin, levofloxacin, moxifloxacin, erythromycin, clindamycin, quinuprime, linezolid, tetracycline, vancomycin, and tigecycline. All susceptibility tests and the interpretation of the results were performed according to the guidelines and criteria established by the Clinical and Laboratory Standard Institute (CLSI), 2017 standard. We used *Staphylococcus aureus* (ATCC 29213) as a quality-control strain in each set of tests to ensure the accuracy of the results.

## Detection of Drug-Resistance Genes

PCR testing using multipair primers ([Table S1](#)) for seven genes (*mreA*, *ermA*, *ermB*, *ermC*, *mefA*, *mefE* and *ermTR*), one gene (*linB*), and four genes (*tetM*, *tetK*, *tetL* and *tetO*) was used to detect drug-resistance genes for erythromycin, clindamycin, and tetracycline, respectively. The PCR products were analyzed by gel electrophoresis and sequenced by the Sangon Biotech Co., Ltd. (Shanghai, China). The positive products were confirmed using the Basic Local Alignment Search Tool (BLAST) (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

## Detection of Virulence Genes

Five virulence genes, *scpB*, *hylB*, *rib*, *bca* and *bac* were detected by PCR using the primer pairs ([Table S1](#)). The PCR products were analyzed using gel electrophoresis and sequenced by the Sangon Biotech Co., Ltd. The positive products were confirmed using BLAST.

## Statistical Analysis


The statistical analysis was performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA). The Chi-square test or Fisher's exact test was used testing categorical data for statistical significance. *P*-values <0.05 were considered to be statistically significant.

## Results

A total of 140 non-duplicate GBS isolates were isolated from vaginal/cervical swabs of pregnant women with PROM. Seventeen ST types were identified by MLST analysis. Specifically, the predominant ST type was ST19 (20.0%, 28/140), followed by ST862 (14.3%, 20/140), ST10 (12.1%, 17/140), ST12 (11.4%, 16/140), ST17 (7.1%, 10/140), and ST27 (7.1%, 10/140). Three CCs were identified: CC19 (27.1%, 38/140), CC10 (25.0%, 35/140) and CC1 (6.4%, 9/140) ([Figure 1](#)).

Five serotypes were identified among 140 strains. The most prevalent serotype was III, accounting for 45.7% (64/140) of isolates, followed by V (23.6%, 33/140), Ib (18.6%, 26/140), Ia (7.1%, 10/140), II (3.6%, 5/140) and non-typeable (NT) (1.4%, 2/140) ([Table 1](#)).

The minimum spanning tree showed good concordance between certain STs and serotypes. The most prevalent ST-serotype combinations were ST19/III (13.6%, 19/140) and ST862/III (13.6%, 19/140). The majority of ST862 (95%, 19/20),



**Figure 1** Distribution diagram of MLST for all the GBS strains.  
**Abbreviations:** MLST, multilocus sequence typing; ST, sequence type; CC, clonal complex.


ST17 (90%, 9/10), ST651 (100%, 3/3), and ST19 (68%, 19/28) isolates were serotype III, whereas the majority of ST529 and ST24 isolates were serotype V. ST23 and ST103 accounted for 80% of serotype Ia isolates, and ST12 and ST10 accounted for 88.5% of serotype Ib isolates (Figure 2 and Table 1).

All isolates were susceptible to penicillin G, ampicillin, quinupristin, linezolid, vancomycin, and tigecycline, whereas most of the isolates were resistant to erythromycin (70.0%), clindamycin (72.1%), tetracycline (81.4%), levofloxacin (28.6%) and moxifloxacin (28.6%) (Table 2). Overall, 102 (72.8%) isolates were multidrug resistant (MDR); for example, all the erythromycin-resistant strains were also resistant to clindamycin. Of the clindamycin-resistant strains, 96% (70/73) were resistant to erythromycin, and 4% (3/73) had an intermediate level of resistance to erythromycin. Moreover, 28.6% of strains were co-resistant to levofloxacin and moxifloxacin. Notably, the minimum inhibitory concentration (MIC) of tetracycline-resistant strains was relatively high, with an MIC required to inhibit 50% of organisms (MIC50)  $\geq 16 \mu\text{g/mL}$ .

**Table 1** Genotype Diversity of Five Serotype Distribution Among 140 Strains

Serotypes	No. (%)	ST
Ia	10 (7.1%)	ST23(4), ST103(4), ST4(1), ST19(1)
Ib	26 (18.6%)	ST12(14), ST10(9), ST17(1), ST358(1), ST862(1)
II	5 (3.6%)	ST10(5)
III	64 (45.7%)	ST19(19), ST862(19), ST17(9), ST27(5), ST1(3), ST2(3), ST651(3), ST12(1), ST24(1), ST167(1)
V	33 (23.6%)	ST529(9), ST19(7), ST27(5), ST24(4), ST10(3), ST23(2), ST2(1), ST3(1), ST358(1)
NT	2 (1.4%)	ST12(1), ST19(1)

**Abbreviations:** NT, non-typeable; ST, sequence type.



**Figure 2** Minimum spanning tree of the relationship between STs and serotypes.  
**Abbreviations:** ST, sequence type. NT, non-typeable.

The antibiotic-resistance profile varied by ST (Table S2), and all ST17, ST19 and ST529 isolates were MDR strains. Almost all (>90%) of ST12, ST17, ST19, ST27, and ST529 isolates were resistant to tetracycline. The predominant STs of levofloxacin-resistant and moxifloxacin-resistant were ST19 (96%) and ST10 (65%). Similar comparisons by serotype showed that the majority (>80%) of serotype Ib and V isolates were resistant to erythromycin and clindamycin (Table S3).

Among the GBS isolates, 70.0% (98/140), 72.1% (101/140), and 81.4% (114/140) strains were erythromycin-, clindamycin-, and tetracycline-resistant, respectively (Table 3). Of the 98 erythromycin-resistant strains, *mreA* was detected in 100% (98/98), followed by *ermB* (70.4%, 69/98), *mefA* (49.0%, 48/98), *mefE* (22.4%, 22/98), *ermA* (13.3%, 13/98) and *ermTR* (9.2%, 9/98), whereas no *ermC*-carrying strains were detected. Of the 101 clindamycin-resistant strains, no *linB*-

**Table 2** Antimicrobial Susceptibility and MIC Distributions of GBS Isolates

Agent	Breakpoint (µg/mL)			MIC (µg/mL)			Antimicrobial Susceptibility		
	S	I	R	Range	MIC50	MIC90	R%	I(%)	S(%)
Erythromycin	≤0.25	0.5	≥1	≤0.25-≥8	1	≥8	70.0%	2.1%	27.9%
Clindamycin	≤0.25	0.5	≥1	≤0.25-≥8	≤0.25	≥8	72.1%	0.7%	27.2%
Tetracycline	≤2	4	≥8	≤1-≥16	≥16	≥16	81.4%	0.0%	18.6%
Levofloxacin	≤2	4	≥8	0.5-≥8	1	≥8	28.6%	1.4%	70.0%
Moxifloxacin	≤1	2	≥4	≤0.25-≥8	≤0.25	4	28.6%	0.7%	70.7%
Penicillin G	≤0.12	-	-	≤0.12	≤0.12	≤0.12	0.0%	0.0%	100.0%
Ampicillin	≤0.25	-	-	≤0.25	≤0.25	≤0.25	0.0%	0.0%	100.0%
Quinupristin	≤1	2	≥4	≤0.25-1	≤0.25	0.5	0.0%	0.0%	100.0%
Linezolid	≤2	-	-	1-2	2	2	0.0%	0.0%	100.0%
Vancomycin	≤1	-	-	≤0.5-1	≤0.5	≤0.5	0.0%	0.0%	100.0%
Tigecycline	≤0.25	-	-	≤0.12	≤0.12	≤0.12	0.0%	0.0%	100.0%

**Abbreviations:** R, resistant; I, intermediate; S, susceptible; MIC, minimum inhibitory concentration.

**Table 3** The Drug-Associated Gene Detection for Erythromycin-, Clindamycin-, and Tetracycline-Resistant Strains

Agents	No.	Genes	No.	Ratio (%)
Erythromycin	98	<i>mreA</i>	98	100.0
		<i>ermA</i>	13	13.3
		<i>ermB</i>	69	70.4
		<i>ermC</i>	0	0.0
		<i>mefA</i>	48	49.0
		<i>mefE</i>	22	22.4
		<i>ermTR</i>	9	9.2
Clindamycin	101	<i>linB</i>	0	0.0
Tetracycline	114	<i>tetM</i>	60	52.6
		<i>tetK</i>	70	61.4
		<i>tetL</i>	9	7.9
		<i>tetO</i>	27	23.7

carrying strains were detected. Of the 114 tetracycline-resistant strains, *tetM*, *tetK*, *tetL* and *tetO* was detected in 52.6% (60/114), 61.4% (70/114), 7.9% (9/114), and 23.7% (27/114), respectively. Of the erythromycin-resistant strains *mreA-ermB*, *mreA-ermB-mefA* and *mreA-mefA-mefE*, was detected in 41.8% (41/98), 18.4% (18/98), and 14.3% (14/98), respectively (Table 4). Of the isolates carrying *mreA-ermB*, the MIC was 0.5–≥8 µg/mL, with an MIC50 ≥4 µg/mL. Of the isolates carrying *mreA-ermB-mefA*, the MIC was 0.5–≥8 µg/mL, with a MIC50 ≥8 µg/mL. Of the isolates carrying *mreA-mefA-mefE*, the MIC was 2–≥8 µg/mL, and 71% had a MIC ≥8 µg/mL.

Five virulence genes were detected in the 140 strains. All strains carried *rib* and *hylB*, followed by *scpB* (98.6%, 138/140), and *bca* (80.7%, 113/140), whereas only one strain carried *bac*. The prevalence of *bca* varied from 45–100% among the seven main STs (Table 5). However, there were no statistically significant differences in the prevalence of the five virulence genes among the different serotypes (data not shown).

**Table 4** Resistance Genes Profile and Minimum Inhibitory Concentration in 98 Erythromycin-Resistant Strains

Erythromycin							No. (%)	MIC(µg/mL)					
<i>mreA</i>	<i>ermA</i>	<i>ermB</i>	<i>ermC</i>	<i>mefA</i>	<i>mefE</i>	<i>ermTR</i>		≤0.25	0.5	1	2	4	≥8
+		+					41 (41.8%)	0	10	8	2	5	16
+		+		+			18 (18.4%)	0	4	3	0	2	9
+				+	+		14 (14.3%)	0	0	0	2	2	10
+				+			4 (4.1%)	0	0	1	0	0	3
+	+			+	+	+	3 (3.1%)	0	0	0	0	0	3
+		+		+	+		3 (3.1%)	1	0	0	0	0	2
+	+					+	3 (3.1%)	0	2	0	0	0	1
+	+	+					2 (2.0%)	0	0	0	0	0	2
+							2 (2.0%)	0	0	0	0	1	1
+	+	+				+	1 (1.0%)	0	0	0	0	0	1
+	+			+		+	1 (1.0%)	0	0	0	0	0	1
+	+			+			1 (1.0%)	0	0	0	0	0	1
+		+			+		1 (1.0%)	0	0	0	0	0	1
+				+	+	+	1 (1.0%)	0	0	0	0	0	1
+	+	+		+		+	1 (1.0%)	0	0	0	0	1	0
+	+	+		+			1 (1.0%)	0	1	0	0	0	0
+		+		+		+	1 (1.0%)	0	0	1	0	0	0

**Abbreviations:** MIC, minimum inhibitory concentration. +, resistance gene detected.



**Table 5** Virulence Gene Detection in 140 Isolates

Virulence gene	No. (%)	ST10 (n=17)	ST12 (n=16)	ST17 (n=10)	ST19 (n=28)	ST27 (n=10)	ST529 (n=9)	ST862 (n=20)	Others (n=30)	P
<i>scpB</i>	138 (98.6%)	17 (100%)	16 (100%)	10 (100%)	28 (100%)	10 (100%)	9 (100%)	19 (95%)	29 (96.7%)	0.914
<i>hylB</i>	140 (100%)	17 (100%)	16 (100%)	10 (100%)	28 (100%)	10 (100%)	9 (100%)	20 (100%)	30 (100%)	–
<i>Rib</i>	140 (100%)	17 (100%)	16 (100%)	10 (100%)	28 (100%)	10 (100%)	9 (100%)	20 (100%)	30 (100%)	–
<i>bca</i>	113 (80.7%)	16 (94.1%)	16 (100%)	9 (90%)	24 (85.7%)	7 (70%)	6 (66.7%)	9 (45%)	26 (86.7%)	<b>0.001</b>
<i>bac</i>	1 (0.7%)	1 (5.9%)	0	0	0	0	0	0	0	–

**Note:** Bolded text highlighted the P-values if <0.05.

**Abbreviation:** ST, sequence type.

## Discussion

GBS colonization in late pregnancy is associated with PROM, perinatal infection, and neonatal GBS-EOD. The GBS colonization rate varies according to ethnicity, region, and individual factors. A previous study reported a GBS colonization rate of 5.3% (29/537) among women in late pregnancy in Fuzhou, China,<sup>24</sup> but the molecular characteristics such as the serotype distribution, MLST analysis, drug-resistance genes, and virulence genes were not reported. In this study, we describe the molecular characteristics and drug susceptibility profile of GBS colonized in pregnant women with PROM.

A total of 17 STs were identified among the 140 GBS strains, with ST19, ST862, ST10, ST12, ST17, and ST27 being higher prevalent. These six predominant STs are similar to those of women from Xiamen (Fujian, China) in late pregnancy.<sup>21</sup> Notably, ST862 was the second most prevalent type in Fuzhou and Xiamen, but it has not been reported in studies conducted in other parts of China.<sup>25–27</sup> Five serotypes (Ia, Ib, II, III, and V) were identified in 98.6% of the GBS strains isolated. A recent review reported that 85% serotypes of GBS isolates from pregnant women in worldwide were Ia, Ib, II, III, and V,<sup>28</sup> and that these serotypes accounted for 96% and 93% of GBS strains in the United States and Europe, respectively. These results suggested that the development of a broad-coverage GBS vaccine (Ia, Ib, II, III, and V) would provide protection against infection by the majority of strains worldwide.

ST19/III and ST862/III were the most prevalent in this region, each accounting for 13.6%. ST862, ST17, ST651, and ST190 were mainly associated with serotype III; ST529 and ST24 were mainly associated with serotype V; ST23 and ST103 were mainly associated with serotype Ia; and ST12 and ST10 were mainly associated with serotype Ib. As the sample sizes and types of patients recruited were varied in previous studies,<sup>21,29–31</sup> it is not possible to compare the results of this study with those of previous studies.

Clinically, penicillin is still recognized as a first-line antibiotic for IAP and treatment of GBS infections. In this study, all the isolates were susceptible to penicillin G, ampicillin, quinupristin, linezolid, vancomycin, and tigecycline. Considering the 0.7–10% prevalence of penicillin allergies,<sup>32</sup> clindamycin, erythromycin, and levofloxacin are important alternatives. However, this study showed a high prevalence of resistance to clindamycin (72.1%), erythromycin (70.0%) and tetracycline (81.4%), suggesting that these agents should not be used as alternatives in patients with penicillin allergies in the absence of drug susceptibility testing. The levofloxacin-resistance rate in this study (28.6%) is similar to that reported in Shanghai (35.5%),<sup>33</sup> but higher than that reported in other countries.<sup>34,35</sup> Differences in antibiotic use could be a major contributor to geographic differences in the prevalence of antimicrobial resistance. From a public health perspective, having additional drugs with which to treat GBS would be useful. This requires taking actions to mitigate AMR in areas with a high prevalence of AMR, such as drug susceptibility testing to select appropriate agents for IAP and treatment, instead of empirical drug use.

All erythromycin-resistant strains carried *mreA*, followed by *ermB*, *mefA*, *mefE*, *ermA*, and *ermTR*, whereas no *ermC*-carrying strains were identified. Furthermore, most erythromycin-resistant strains carried *mreA-ermB*, *mreA-ermB-mefA* or *mreA-mefA-mefE*, which tended to have higher MIC50 levels. These results suggest that the “efflux pump”, mediated by *mreA* and *mefA/E*, is an important resistance mechanism. The high prevalence of *ermB* suggests that GBS commonly uses target methylation as the mechanism of macrolide resistance. No *linB* was detected among the 101 clindamycin-resistant strains, suggesting that clindamycin resistance is related to other resistance mechanisms. Of the 114 tetracycline-

resistant strains, *tetM*, *tetK*, *tetL* and *tetO* were detected. This suggests that tetracycline resistance is mediated by ribosomal protection proteins encoded mainly by the *tetM* or *tetO* genes and “efflux pumps” encoded by the *tetK* or *tetL* genes.

GBS virulence is also important for the development of vaccines and for understanding its pathogenicity. All strains carried *rib* and *hylB*, and the majority of strains carried *scpB*, and *bca*, whereas only one strain carried *bac*. Moreover, the prevalence of *bca* varied among the seven main STs, and was lowest for ST862 but highest for ST12. These results suggest that GBS bacterial surface proteins encoded by *rib*, *hylB*, and *scpB* may be candidates for antigenic epitopes of vaccines, whereas *bac* with a very low detection rate (<1%) is not a suitable candidate.

Of note, ST862 and ST651 are emerging zoonotic STs which are the main cause of bovine mastitis.<sup>36</sup> ST862 has become the second most prevalent type in Fujian province (including Fuzhou and Xiamen). As mentioned above, 95% of ST862 and all the ST651 strains were identified as serotype III. For ST862 strains, the resistance rate to erythromycin, clindamycin, and tetracycline were 60%, 65% and 65%, respectively, and a low carry rate (45%) of *bca* virulence gene was observed. As bovine *S. agalactiae* may be affected by the selection pressure of antibiotic treatment for mastitis, further information is needed on the antibiotic resistance profile of *S. agalactiae* STs of animal origin in the Fuzhou region.

This study had some limitations. First, the D-test was not performed on GBS strains showing resistance to erythromycin and clindamycin to test for inducible macrolide resistance. Second, no cases of neonatal GBS-EOD were diagnosed during the study period, because all pregnant women with PROM received IAP, and no cases of neonatal GBS infection occurred.

## Conclusions

We determined the molecular epidemiology of GBS in pregnant women with PROM in Fuzhou City, China. The predominant STs were ST19, ST862, ST10, and ST12, and the three CCs were CC19, CC10, and CC1. The most prevalent serotypes were III, V, and Ib. All isolates were susceptible to penicillin G, ampicillin, quinupristin, linezolid, vancomycin, and tigecycline, and highly resistant to erythromycin, clindamycin, tetracycline, levofloxacin, and moxifloxacin. The common erythromycin-resistance genes were *mreA*, *ermB*, *mefA* and *mefE*, and the common tetracycline-resistance genes were *tetK* and *tetM*. The predominant virulence genes were *rib*, *hylB*, *scpB*, and *bca*. It should draw the attention that ST862 and ST651 as emerging zoonotic STs that may become a potential threat. This study provides a comprehensive description of the molecular epidemiology of GBS in the Fuzhou region, and the results can be used to inform the prevention and treatment of perinatal GBS disease.

## Abbreviations

CPS, capsular polysaccharide; EOD, early-onset disease; GBS, Group B *Streptococcus*; AMR, antimicrobial resistance; MLST, multilocus sequence typing; PROM, premature rupture of the membranes; ST, sequence type; CC, clonal complex.

## Data Sharing Statement

The data that support the findings of this study are openly available in figshare.2014. (<https://doi.org/10.6084/m9.figshare.20584314.v2>).

## Ethics Approval and Consent to Participate

This study was approved by the Ethics Committee of the Fujian Maternity and Child Care Hospital (No.2019–066). Informed consent was obtained from all the participants prior to enrollment. Our study was carried out followed the principles outlined in the Declaration of Helsinki.

## Acknowledgments

We are grateful to the patients for their collaboration.



## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, drafting and revising the article, gave final approval of the version to be published, have agreed on the journal to which the article will be submitted and agreed to be accountable for all aspects of the work. The final manuscript was reviewed and approved by all authors.

## Funding

This work was supported by grants from Fujian Provincial Natural Science Foundation (2020J05275); Fujian Provincial Maternity and Child Health Hospital [grant no. YCXM 19-15]; and Fujian Provincial Maternity and Child Health Hospital [grant no. YCXM 20-30].

## Disclosure

The authors declare that they have no competing interests in this work.

## References

1. Russell NJ, Seale AC, O'Driscoll M, et al. Maternal colonization with Group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. *Clin Infect Dis*. 2017;65(suppl\_2):S100–S111. doi:10.1093/cid/cix658
2. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. *Lancet*. 2012;379(9815):547–556. doi:10.1016/S0140-6736(11)61651-6
3. Naat G, Encourage PC. Prevention of Group B Streptococcal early-onset disease in newborns: ACOG committee opinion, number 797. *Obstet Gynecol*. 2020;135(2):e51–e72. doi:10.1097/AOG.0000000000003668
4. Chu YW, Tse C, Tsang GK, So DK, Fung JT, Lo JY. Invasive group B Streptococcus isolates showing reduced susceptibility to penicillin in Hong Kong. *J Antimicrob Chemother*. 2007;60(6):1407–1409. doi:10.1093/jac/dkm390
5. Kimura K, Suzuki S, Wachino J, et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. *Antimicrob Agents Chemother*. 2008;52(8):2890–2897. doi:10.1128/AAC.00185-08
6. Nagano N, Nagano Y, Toyama M, et al. Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1. *J Antimicrob Chemother*. 2012;67(4):849–856. doi:10.1093/jac/dkr546
7. Dahesh S, Hensler ME, Van Sorge NM, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. *Antimicrob Agents Chemother*. 2008;52(8):2915–2918. doi:10.1128/AAC.00461-08
8. Yi A, Kim CK, Kimura K, et al. First Case in Korea of Group B Streptococcus with reduced penicillin susceptibility harboring amino acid substitutions in penicillin-binding protein 2X. *Ann Lab Med*. 2019;39(4):414–416. doi:10.3343/alm.2019.39.4.414
9. Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Systematic review and meta-analyses of incidence for Group B Streptococcus disease in infants and antimicrobial resistance, China. *Emerg Infect Dis*. 2020;26(11):2651–2659. doi:10.3201/eid2611.181414
10. Hayes K, O'Halloran F, Cotter L. A review of antibiotic resistance in Group B Streptococcus: the story so far. *Crit Rev Microbiol*. 2020;46(3):253–269. doi:10.1080/1040841X.2020.1758626
11. Francois Watkins LK, McGee L, Schrag SJ, et al. Epidemiology of Invasive Group B Streptococcal infections among nonpregnant adults in the United States, 2008–2016. *JAMA Intern Med*. 2019;179(4):479–488. doi:10.1001/jamainternmed.2018.7269
12. Maeda T, Takayama Y, Fujita T, et al. Comparison between invasive and non-invasive streptococcus agalactiae isolates from human adults, based on virulence gene profiles, capsular genotypes, sequence types, and antimicrobial resistance patterns. *Jpn J Infect Dis*. 2021;74(4):316–324. doi:10.7883/yoken.JJID.2020.761
13. Van Du V, Dung PT, Toan NL, et al. Antimicrobial resistance in colonizing group B Streptococcus among pregnant women from a hospital in Vietnam. *Sci Rep*. 2021;11(1):20845. doi:10.1038/s41598-021-00468-3
14. Wang CH, Kung WJ, Lee CH, et al. High rates of colonization and antimicrobial resistance of group B streptococcus highlight the need for vaccination even after implementation of guidelines for intrapartum antibiotic prophylaxis. *Vaccine*. 2022;40(2):282–287. doi:10.1016/j.vaccine.2021.11.069
15. Heath PT. Status of vaccine research and development of vaccines for GBS. *Vaccine*. 2016;34(26):2876–2879. doi:10.1016/j.vaccine.2015.12.072
16. Zhu Y, Wu J, Zheng X, et al. Etiological serotype and genotype distributions and clinical characteristics of group B streptococcus-inducing invasive disease among infants in South China. *BMC Pediatr*. 2020;20(1):146. doi:10.1186/s12887-020-02048-2
17. Nanduri SA, Petit S, Smelser C, et al. Epidemiology of invasive early-onset and late-onset Group B Streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance. *JAMA Pediatr*. 2019;173(3):224–233. doi:10.1001/jamapediatrics.2018.4826
18. Furfaro LL, Chang BJ, Payne MS. Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets. *Clin Microbiol Rev*. 2018;31(4):e00049–18. doi:10.1128/CMR.00049-18
19. Shabayek S, Spellerberg B. Group B Streptococcal colonization, molecular characteristics, and epidemiology. *Front Microbiol*. 2018;9:437. doi:10.3389/fmicb.2018.00437
20. Shabayek S, Ferrieri P, Spellerberg B. Group B Streptococcal Colonization in African countries: prevalence, capsular serotypes, and molecular sequence types. *Pathogens*. 2021;10:12. doi:10.3390/pathogens10121606
21. Yao Z, Jiayin W, Xinyi Z, et al. Identification of Group B Streptococcus serotypes and genotypes in late pregnant women and neonates that are associated with neonatal early-onset infection in a South China Population. *Front Pediatr*. 2020;8:265. doi:10.3389/fped.2020.00265
22. Jones N, Bohnsack JF, Takahashi S, et al. Multilocus sequence typing system for group B streptococcus. *J Clin Microbiol*. 2003;41(6):2530–2536. doi:10.1128/JCM.41.6.2530-2536.2003

23. Alhazmi A, Pandey A, Tyrrell GJ. Identification of Group B Streptococcus Capsule type by use of a dual phenotypic/genotypic assay. *J Clin Microbiol.* 2017;55(9):2637–2650. doi:10.1128/JCM.00300-17
24. Huang LR, Wang Y, Wang WQ, Ying W, Wang LB, Pan HY. Drug resistance analysis of Streptococcus agalactiae in urogenital tract of women in late pregnancy in Fuzhou area. *Chin J Health Lab Tec.* 2020;30(20):2470–2472.
25. Li J, Ji W, Gao K, et al. Molecular characteristics of group B Streptococcus isolates from infants in southern mainland China. *BMC Infect Dis.* 2019;19(1):812. doi:10.1186/s12879-019-4434-0
26. Wang P, Tong JJ, Ma XH, et al. Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates circulating in Beijing, China. *PLoS One.* 2015;10(3):e0120035. doi:10.1371/journal.pone.0120035
27. Jiang H, Chen M, Li T, Liu H, Gong Y, Li M. Molecular characterization of streptococcus agalactiae causing community- and hospital-acquired infections in Shanghai, China. *Front Microbiol.* 2016;7:1308. doi:10.3389/fmicb.2016.01308
28. Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. *Vaccine.* 2013;31(Suppl 4):D31–42. doi:10.1016/j.vaccine.2013.05.012
29. Lo CW, Liu HC, Lee CC, et al. Serotype distribution and clinical correlation of Streptococcus agalactiae causing invasive disease in infants and children in Taiwan. *J Microbiol Immunol Infect.* 2019;52(4):578–584. doi:10.1016/j.jmii.2017.09.002
30. Kao Y, Tsai MH, Lai MY, et al. Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: the clinical characteristics and impacts on outcomes. *BMC Infect Dis.* 2019;19(1):538. doi:10.1186/s12879-019-4177-y
31. Lu B, Li D, Cui Y, Sui W, Huang L, Lu X. Epidemiology of Group B streptococcus isolated from pregnant women in Beijing, China. *Clin Microbiol Infect.* 2014;20(6):O370–3. doi:10.1111/1469-0691.12416
32. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. *Arch Intern Med.* 2001;161(1):15–21. doi:10.1001/archinte.161.1.15
33. Yan Y, Hu H, Lu T, et al. Investigation of serotype distribution and resistance genes profile in group B Streptococcus isolated from pregnant women: a Chinese multicenter cohort study. *APMIS.* 2016;124(9):794–799. doi:10.1111/apm.12570
34. Safari D, Gultom SM, Tafroji W, et al. Prevalence, serotype and antibiotic susceptibility of Group B Streptococcus isolated from pregnant women in Jakarta, Indonesia. *PLoS One.* 2021;16(5):e0252328. doi:10.1371/journal.pone.0252328
35. Piccinelli G, Gargiulo F, Corbellini S, et al. Emergence of the first levofloxacin-resistant strains of Streptococcus agalactiae isolated in Italy. *Antimicrob Agents Chemother.* 2015;59(4):2466–2469. doi:10.1128/AAC.05127-14
36. Carvalho-Castro GA, Silva JR, Paiva LV, et al. Molecular epidemiology of Streptococcus agalactiae isolated from mastitis in Brazilian dairy herds. *Braz J Microbiol.* 2017;48(3):551–559. doi:10.1016/j.bjm.2017.02.004

## Infection and Drug Resistance

Dovepress

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>